Kymera Therapeutics (NASDAQ:KYMR) Shares Down 1.9% After Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report)’s stock price traded down 1.9% during trading on Monday after an insider sold shares in the company. The company traded as low as $36.22 and last traded at $36.49. 178,419 shares were traded during mid-day trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at $37.21.

Specifically, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.58, for a total value of $74,401.10. Following the transaction, the insider now owns 34,205 shares in the company, valued at approximately $772,348.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Kymera Therapeutics news, insider Jared Gollob sold 46,137 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $35.50, for a total value of $1,637,863.50. Following the transaction, the insider now owns 74,709 shares in the company, valued at $2,652,169.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $22.58, for a total transaction of $74,401.10. Following the sale, the insider now directly owns 34,205 shares in the company, valued at approximately $772,348.90. The disclosure for this sale can be found here. Insiders have sold a total of 59,432 shares of company stock worth $2,012,765 in the last 90 days. 16.67% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright cut their target price on shares of Kymera Therapeutics from $85.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Piper Sandler dropped their price objective on shares of Kymera Therapeutics from $58.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Bank of America lowered shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $45.00 to $30.00 in a research note on Wednesday, January 3rd. Leerink Partnrs reissued a “market perform” rating on shares of Kymera Therapeutics in a research note on Monday, October 16th. Finally, Wells Fargo & Company lowered shares of Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 price objective on the stock. in a research note on Tuesday, December 19th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.88.

Get Our Latest Research Report on KYMR

Kymera Therapeutics Price Performance

The firm’s 50 day moving average price is $27.99 and its 200-day moving average price is $21.06. The stock has a market cap of $2.02 billion, a P/E ratio of -12.69 and a beta of 2.23.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KYMR. Amundi purchased a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $49,000. Point72 Hong Kong Ltd purchased a new position in shares of Kymera Therapeutics during the first quarter valued at approximately $53,000. Advisors Asset Management Inc. purchased a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $58,000. Royal Bank of Canada raised its holdings in shares of Kymera Therapeutics by 30.0% during the second quarter. Royal Bank of Canada now owns 2,773 shares of the company’s stock valued at $64,000 after purchasing an additional 640 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Kymera Therapeutics by 65.4% during the second quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company’s stock valued at $67,000 after buying an additional 1,146 shares during the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Stories

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.